‘At The End Of The Day, It’s A Huge, Huge Opportunity’ – Teva’s Rainey Talks Stelara

Tom Rainey, SVP Of US Market Access At Teva, Discusses The Firm’s US Biosimilars Business

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Teva is ramping up its activities in US biosimilars, with the launch of its Alvotech-partnered Humira rival imminent and a Stelara biosimilar slated for launch in February 2025. Tom Rainey, the firm’s senior vice president of US market access, talks about the opportunities on the horizon and how the firm is balancing its partnership model with in-house development.

Teva logo outside company building
Teva is eyeing biosimilar opportunities • Source: Shutterstock

With Teva recently gaining two US Food and Drug Administration biosimilar approvals in quick succession for its Alvotech-partnered Humira (adalimumab) and Stelara (ustekinumab) rivals, the company’s CEO Richard Francis recently talked in detail about how the firm sees the adalimumab market shaping up ahead of the firm’s imminent launch of its Simlandi (adalimumab-ryvk) version. (Also see "Teva Plans To Launch Six Biosimilars By 2027" - Generics Bulletin, 14 May, 2024.)

But coming just a matter of months after that launch will be a second, arguably even more meaningful biosimilar launch...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.